FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease

Ads

You May Also Like

Cesca Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa

RANCHO CORDOVA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...

NeoTherma Oncology Raises $6 Million to Advance VectRx™ to Human Testing

WICHITA, Kan., Aug. 14, 2018 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), developer of an ...